Burgundy Asset Management Ltd. Has $151.05 Million Stock Holdings in Henry Schein, Inc. $HSIC

Burgundy Asset Management Ltd. lowered its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,170,871 shares of the company’s stock after selling 36,622 shares during the quarter. Henry Schein accounts for about 1.4% of Burgundy Asset Management Ltd.’s investment portfolio, making the stock its 29th biggest holding. Burgundy Asset Management Ltd. owned about 1.84% of Henry Schein worth $151,049,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. CYBER HORNET ETFs LLC bought a new stake in shares of Henry Schein in the 2nd quarter valued at $25,000. MUFG Securities EMEA plc acquired a new stake in shares of Henry Schein during the second quarter worth about $27,000. Sentry Investment Management LLC raised its position in shares of Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after purchasing an additional 515 shares during the period. Evelyn Partners Investment Management Services Ltd bought a new position in shares of Henry Schein during the 2nd quarter valued at about $62,000. Finally, Mather Group LLC. acquired a new position in shares of Henry Schein in the 3rd quarter valued at approximately $71,000. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Henry Schein news, CEO Stanley M. Bergman sold 43,812 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares of the company’s stock, valued at $31,207,021.93. The trade was a 10.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 92,943 shares of company stock worth $7,544,505 in the last three months. Company insiders own 1.08% of the company’s stock.

Henry Schein Price Performance

NASDAQ:HSIC opened at $80.58 on Thursday. The stock has a market capitalization of $9.24 billion, a PE ratio of 24.64, a P/E/G ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $89.29. The firm has a fifty day simple moving average of $78.09 and a 200 day simple moving average of $72.44. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The company’s quarterly revenue was up 7.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have weighed in on HSIC. Wall Street Zen upgraded shares of Henry Schein from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research report on Monday, December 29th. Evercore increased their target price on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, November 5th. JPMorgan Chase & Co. boosted their price target on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Wells Fargo & Company increased their price objective on Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.